Pradžia › Imuninė sistema ir sutrikimai › Texas
Imuninė sistema ir sutrikimai klinikiniai tyrimai Texas
14 tyrimai dėl Imuninė sistema ir sutrikimai ieško dalyvių vietose Texas.
Miestai Texas
Oficialus tyrimo tekstas (anglų kalba)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- The University of Texas - MD Anderson Cancer Center, Houston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT07192471A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Jade Clinical Site, Houston
Renkami dalyviai2 fazė
Amžius nuo 18 iki 60 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07541287A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Baylor College of Medicine, Houston
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-18 · NCT06722235Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- The Don and Sybil Harrington Cancer Center, Amarillo
- Audie L Murphy VA Hospital, San Antonio
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-09-17 · NCT04242095(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- The University of Texas MD Anderson Cancer Center, Houston
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-15 · NCT04996875A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Baylor College of Medicine, Houston
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-09 · NCT06948318Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Baylor University Medical Center, Dallas
- Texas Transplant Institute, San Antonio
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-25 · NCT05826535Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- Dallas Renal Group, Dallas
- Dallas Renal Group, Dallas
- Nephro Asso North Illinois Indiana, Houston
Renkami dalyviai3 fazė
Amžius nuo 18 iki 100 · Visoms lytims · Atnaujinta 2026-08-17 · NCT06858319Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study
- University of Texas at Austin, Austin
Renkami dalyviai
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-08-17 · NCT07759115A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 8, Southlake
Renkami dalyviai2 fazė
Amžius nuo 18 iki 74 · Visoms lytims · Atnaujinta 2026-08-12 · NCT07037901A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
- Texas Children's Hospital, Houston
Renkami dalyviai2 fazė
Visi amžiai · Visoms lytims · Atnaujinta 2026-06-02 · NCT05787574A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- UT Southwestern Medical Center, Dept. of Dermatology, Dallas
- MD Anderson Texas Medical Center, Houston
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-29 · NCT04422912CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- The University of Texas MD Anderson Cancer Center, Houston
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-16 · NCT03328078A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- St. David's South Austin Medical Center, Austin
- UT Southwestern Medical Center, Dallas
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-12-15 · NCT06619561Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.